Drug Profile

Anti CD40 HPV vaccine - EnnoDC

Alternative Names: Anti-CD40 HPV vaccine - EnnoDC; CD40.HVac; CD40HVac; HPV anti-CD40 HPV vaccine

Latest Information Update: 07 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaccine Research Institute
Developer EnnoDC
Class Papillomavirus vaccines; Protein vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Human papillomavirus infections

Most Recent Events

06 Mar 2025 EnnoDC plans to initiate phase IIb trial in Human papillomavirus infections (Prevention) in Q1 2025 (Parenteral) (EnnoDC pipeline, March 2025)
26 Sep 2024 LinKinVax is now called EnnoDC
26 Sep 2024 EnnoDC plans a pre-IND filing for a phase I/IIa trial in Prostate cancer in early 2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com